FDB Leverages AI to Automate ePrescribing, Reducing Pharmacy Workload

Event summary

  • FDB is presenting at the NCPDP Annual Conference on May 5, 2026, focusing on AI's impact on ePrescribing.
  • Brad Engels, FDB's senior product manager, will lead a session titled 'First Steps of AI's Revolutionary Impact on Prescription Processing'.
  • FDB is highlighting AI-driven solutions like MedProof MCP, Script Agent, and VerifyAssist to automate prescription workflows.
  • The session will explore how AI can improve accuracy, reduce manual steps, and enhance interoperability across prescribing and pharmacy settings, particularly with NCPDP SCRIPT transactions.

The big picture

FDB's focus on AI-driven automation addresses a long-standing pain point in the ePrescribing process – the significant manual effort required by clinicians and pharmacists. This move positions FDB to capitalize on the growing demand for interoperable healthcare solutions and potentially reduce the administrative burden on healthcare providers, a key driver in cost containment efforts. The integration of ambient AI and NLP capabilities represents a significant advancement in automating complex tasks and improving accuracy within the prescription lifecycle.

What we're watching

Adoption Rate
The pace at which pharmacies and prescribers adopt FDB's AI-powered tools will determine the realized impact on workflow efficiency and cost savings, and will be a key indicator of FDB's market penetration.
Regulatory Scrutiny
Increased reliance on AI in prescription processing may draw regulatory attention regarding data privacy, algorithmic bias, and patient safety, potentially impacting FDB's product development and deployment.
Competitive Landscape
How competitors respond to FDB’s AI-native approach to ePrescribing, and whether they develop similar solutions, will shape the long-term competitive dynamics within the medication workflow automation market.